Jiawei An

Dr. Jiawei An

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2026 in Medicine
Verified
Journal Article
Open access
JAJiawei An
Jiawei An
MZMingyan Zhu
Mingyan Zhu
YFYangsuolang Mmed Fu
Yangsuolang Mmed Fu
KGKai Mmed Gao
Kai Mmed Gao
HXHuien Mmed Xie
Huien Mmed Xie
YXYicheng Xiong
Yicheng Xiong
While some observational research has pointed to a connection between inflammatory bowel disease and increased cirrhosis risk, it has been difficult to determine if this is a genuine cause-and-effect relationship. The challenge lies in separating actual causation from confounding factors that might influence both conditions. In this study, we turned to Mendelian randomization (MR) – a method that uses genetic variations as natural experiments – to investigate whether inflammatory bowel disease (IBD) truly causes cirrhosis. We performed a two-sample MR analysis. Genetic instruments for IBD were obtained from the IBD Genetics Consortium. Cirrhosis outcome data were sourced from both the FinnGen consortium and the UK Biobank, with summary statistics combined via fixed-effects meta-analysis. Methods included inverse-variance weighted, MR-Egger, weighted median, and sensitivity analyses (including Cochran Q test, MR-Egger intercept test, and leave-one-out analysis). The evidence from our MR analysis does not support a causal effect of IBD on cirrhosis risk. Our main analysis using inverse-variance weighted showed an odds ratio of 1.02 (95% confidence interval = 0.97–1.07, P = .42), indicating no significant association. Other methods told the same story, and our sensitivity analyses revealed no concerning heterogeneity or pleiotropy that might undermine these results. Put simply, our findings suggest that IBD does not directly cause cirrhosis. The associations seen in previous observational studies were likely driven by other factors that affect both conditions, rather than a direct biological pathway from IBD to liver damage.